Skip to main content
Clinical Trials/NCT00901628
NCT00901628
Completed
Phase 4

Efficacy and Safety of Periarticular Multimodal Drug Injections in Total Knee Arthroplasty

Seoul National University Hospital1 site in 1 country101 target enrollmentApril 2008

Overview

Phase
Phase 4
Intervention
ropivacaine
Conditions
Osteoarthritis, Knee
Sponsor
Seoul National University Hospital
Enrollment
101
Locations
1
Primary Endpoint
Pain( Visual Analog Scale )
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

The purpose of this study is to determine whether periarticular multimodal drug injection (PMDI) would provide additional benefits in patients after total knee arthroplasty (TKA) for whom contemporary pain control protocols using the continuous femoral nerve block, intra-venous patient controlled analgesia (IV-PCA)and preemptive oral medications. We hypothesized that PMDI would reduce pain level and consumption of PCA and acute pain rescuer and would provide better functional recovery and patient satisfaction. We also hypothesized that the incidence of side effects and complications of the PMDI would be similar to the No-PMDI.

Detailed Description

The preemptive multimodal approaches are regarded as a current standard pain management protocol. Recently, periarticular multimodal drug injection (PMDI) has been considered to be one of the most effective and important component in multimodal approaches. Because the contemporary pain management protocol using the regional anesthesia, continuous femoral nerve block (FNB) and intravenous patient-controlled analgesia (PCA) has been proved significantly improved analgesic effects itself, little information whether the PMDI would provide additional pain relief under this pain management protocol is available. Also, because the safety of the high dose local anesthetics and narcotics has not been clarified, a selective application should be considered to patients who were expected to show better analgesia if there were certain patient related factors to predict the additional pain relief effect of the PMDI. Thus, this prospective double-blind randomized study was conducted to determine whether PMDI would provide additional benefits in patients after total knee arthroplasty (TKA) for whom contemporary pain control protocols using the continuous femoral nerve block, IV-PCA and preemptive oral medications in terms of pain relief, consumption of PCA and acute pain rescuer, patients satisfaction, functional recovery, side effects and complications.

Registry
clinicaltrials.gov
Start Date
April 2008
End Date
April 2009
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Tae Kyun Kim

Joint reconstruction center, Dept. of orthopaedic surgery

Seoul National University Hospital

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of primary osteoarthritis
  • Scheduled for elective total knee arthroplasty
  • Signed written informed consent
  • Spinal anesthesia

Exclusion Criteria

  • Patients refusing consents
  • inability to use the outcome assessment tools
  • Contraindications to regional anesthesia
  • severe cardiovascular disease
  • allergy or contraindication to drugs used in this study
  • pre-existing neurologic disease including psychiatric disorder
  • drug abuser

Arms & Interventions

Periarticular Injection group

Periarticular injection with ropivacaine, morphine, ketorolac, epinephrine, cefuroxime

Intervention: ropivacaine

Periarticular Injection group

Periarticular injection with ropivacaine, morphine, ketorolac, epinephrine, cefuroxime

Intervention: morphine sulfate

Periarticular Injection group

Periarticular injection with ropivacaine, morphine, ketorolac, epinephrine, cefuroxime

Intervention: ketorolac

Periarticular Injection group

Periarticular injection with ropivacaine, morphine, ketorolac, epinephrine, cefuroxime

Intervention: epinephrine

Periarticular Injection group

Periarticular injection with ropivacaine, morphine, ketorolac, epinephrine, cefuroxime

Intervention: cefuroxime

Outcomes

Primary Outcomes

Pain( Visual Analog Scale )

Time Frame: the night after surgery

An independent investigator who was blinded to randomization assessed pain level using 0 to 10 visual analog scale (VAS) that ranged from 0 (no pain) to 10 (worst imaginable pain)at the night after operation.

Secondary Outcomes

  • Intravenous Patient Controlled Analgesia(PCA) Consumption During 24 Hours After Surgery(24 hours postoperative)
  • Participant Number of Postoperative Nausea and Vomiting During 24 Hours After Surgery(24 hours after surgery)
  • the Proportion of Patients Who Were Satisfied With the Pain Management(postoperative 7 day)
  • The Proportion of Patients Who Could Raise Leg With Replaced Knee Extended(24 hours postoperative)
  • Maximal Flexion Angle Degree on Postoperative 7 Day(postoperative 7 day)

Study Sites (1)

Loading locations...

Similar Trials